Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL-231 Phase 1b Trial in Schizophrenia
NCT04136873Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emraclidine in schizophrenia (14 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Incidence of suicidality as assessed by Columbia-Suicide Severity Rating Scale and 3 more. Started Oct 2019; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04136873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136873.